Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merit Medical Systems, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Begins integrating Mallinckrodt catheter unit following completion of the acquisition, announced Aug. 25 (1"The Gray Sheet" July 26, p. 24)

You may also be interested in...



Merit/Mallinckrodt

Merit Medical Systems will acquire Mallinckrodt's $10 mil.-per-year diagnostic and interventional catheter production facility in Angleton, Texas for undisclosed terms under a July 21 agreement in principle. The purchase "strengthens our sales and new product development objectives by adding...revenue as well as providing a depth of core technology for future catheter development," Merit Chairman and CEO Fred Lampropoulos explains. Strategically, the non-core Mallinckrodt business complements Merit's current offerings and will allow consolidation of some existing catheter products into the Angleton facility for greater plant utilization. The deal is expected to close in August subject to a binding agreement. Separately, Merit announces a 28% increase in second-quarter net income to $752,684 on revenues of $19 mil., up 5.6%

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.

DePuy Synthes Gains US FDA Clearance For Velys Robot For Total Knee Surgery

DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel